Stanford University / New York-Presbyterian Hospital / Columbia University Irving Medical Center / Weill Cornell Medicine / Mayo Clinic (Jain, Sun, Pierson et al.)
Training code and model weights not public. Contact creators for more information.
Multimodal machine learning model that flags patients at risk of transthyretin amyloid cardiomyopathy (ATTR-CM) -- a progressive, underdiagnosed disease with expanding disease-modifying treatment options -- from routinely available ECG waveforms, echocardiographic measurements, demographics, and diagnosis codes for orthopedic manifestations of amyloidosis (e.g. carpal tunnel syndrome, spinal stenosis). Developed on 799 patients with 5-fold cross-validation (AUROC 0.85) and externally validated on 422 patients at a separate site (AUROC 0.82), with consistent accuracy across Hispanic, non-Hispanic Black, and non-Hispanic White patients. In a subsequent nonrandomized, single-system, multisite clinical trial (the Cardiac Amyloidosis Discovery Trial), patients flagged by ATTRACTnet and referred for confirmatory amyloid scintigraphy were positive for ATTR-CM 48% of the time, more than 2.8x the positivity rate of historical (15.3%) and contemporary (17.0%) controls referred by usual clinical judgment (P < .001 for both). This is a proprietary clinical AI program; no public code or model weights have been released.
Architecture
Hybrid
Multimodal fusion model combining 12-lead ECG waveform features, echocardiographic measurements, patient demographics, and ICD-coded orthopedic amyloidosis manifestations to output an ATTR-CM risk score
Added to catalog
2026-08-10
New York-Presbyterian/Columbia ATTR-CM Development Cohort
799 patients (mean age 75.1 [SD 11.1]; 64.7% male) evaluated with amyloid scintigraphy, ECG, and echocardiography, used to develop ATTRACTnet via 5-fold cross-validation.
Weill Cornell ATTR-CM External Validation Cohort
422 patients who underwent amyloid scintigraphy at NewYork-Presbyterian/Weill Cornell Medical Center, used as an external test set for ATTRACTnet.
Binary classification of transthyretin amyloid cardiomyopathy (ATTR-CM) risk from ECG waveforms, echocardiographic measurements, demographics, and orthopedic-manifestation diagnosis codes, used to trigger referral for confirmatory amyloid scintigraphy